The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review
Authors:
- 21 December 2007
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 92 (1) , 7-12
Abstract
Aim: To systematically review the literature on the efficacy and harm of prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in treating elevated intraocular pressure (IOP). Methods: Keywords were searched in major literature databases to identify relevant randomised clinical trials (RCTs) of PGAs for ophthalmic use. The study quality of RCTs was assessed using the Jadad scale. Outcomes assessed included reduction in IOP in individual patients, adverse events (AEs) and withdrawals due to AEs. Results: Eight unique RCTs evaluating a total of 1,722 individuals were included in this systematic review. Analysis did not show a significant reduction in the mean IOP from patients receiving latanoprost compared with those receiving brimonidine (WMD = −1.04; p = 0.30). On the other hand, the latanoprost group showed a significant reduction in mean IOP compared to the dorzolamide group (WMD = −2.64; pConclusion: Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. Neither travoprost nor bimatoprost was compared to dorzolamide or brimonidine in the present literature.Keywords
This publication has 24 references indexed in Scilit:
- Persistence and Adherence With Topical Glaucoma TherapyAmerican Journal of Ophthalmology, 2005
- Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trialsBMJ, 2005
- The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patientsEye, 2005
- Latanoprost or Brimonidine as Treatment for Elevated Intraocular PressureJournal of Glaucoma, 2005
- Management of Glaucoma: Focus on Pharmacological TherapyDrugs & Aging, 2005
- New therapies for glaucoma: are they all up to the task?Expert Opinion on Therapeutic Patents, 2004
- Factors for progression and glaucoma treatment: The Early Manifest Glaucoma TrialCurrent Opinion in Ophthalmology, 2004
- The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deteriorationAmerican Journal of Ophthalmology, 2000
- What contributions do languages other than English make on the results of meta-analyses?Journal of Clinical Epidemiology, 2000
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996